MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 26, 2005; DOI: 10.1124/mol.104.007807


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.007807v1
67/5/1406    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Desai, A. D
Right arrow Articles by Cronstein, B. N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desai, A. D
Right arrow Articles by Cronstein, B. N


Received for publication October 5, 2004.
Revised January 26, 2005.
Accepted for publication January 26, 2005.

Adenosine A2A Receptor Stimulation Increases Angiogenesis By Downregulating Production Of The Anti-Angiogenic Matrix Protein Thrombospondin 1 (TSP1)

Avani D Desai 1, Cassandre Victor-Vega 1, Swathi Gadangi 1, M. Carmen Montesinos 1, Charles C Chu 2, Bruce N Cronstein 1*

1 NYU School of Medicine 2 North Shore-LIJ Research Institute

* Address correspondence to: E-mail: cronsb01{at}med.nyu.edu

Abstract

Topical adenosine A2A receptor agonists promote wound healing by, among other effects, increasing microvessel formation. Results of representational display analysis of human umbilical vein endothelial cells suggested that A2A receptor occupancy modulates expression of the anti-angiogenic matrix protein thrombospondin 1 (TSP1). We therefore determined whether A2A receptor occupation stimulates angiogenesis by modulating TSP1 secretion. Human microvascular endothelial cells (HMVEC) were treated with medium alone, CGS-21680 or MRE0094, selective A2A receptor agonists. TSP1 protein secretion was downregulated following treatment with the A2A agonists CGS-21680 or MRE0094 in a dose-dependent manner (EC50=6.65 nM or 0.23 µM, respectively). The selective A2A receptor antagonist ZM241385 but not the A1 and A2B receptor antagonists DPCPX, enprofylline and MRS 1706, completely abrogated the A2A receptor agonist-mediated effect on TSP1. Vascular tube formation by HMVEC was increased by adenosine A2A receptor agonists in a dose-dependent fashion (EC50= 0.1 µM for both) and this effect was reversed by the A2A antagonist. Moreover, in the presence of antibodies to TSP1 and CD36, the receptor for TSP1, the adenosine A2A receptor agonists stimulated no increase in vascular tube formation. These results indicate that the angiogenic effects of adenosine A2A receptor activation are, at least in part, due to suppression of TSP1 secretion.


Key words: Adenosine, Angiogenesis


This article has been cited by other articles:


Home page
FASEB J.Home page
B. Csoka, L. Himer, Z. Selmeczy, E. S. Vizi, P. Pacher, C. Ledent, E. A. Deitch, Z. Spolarics, Z. H. Nemeth, and G. Hasko
Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function
FASEB J, October 1, 2008; 22(10): 3491 - 3499.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
G. Hasko and P. Pacher
A2A receptors in inflammation and injury: lessons learned from transgenic animals
J. Leukoc. Biol., March 1, 2008; 83(3): 447 - 455.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. A. Auchampach
Adenosine Receptors and Angiogenesis
Circ. Res., November 26, 2007; 101(11): 1075 - 1077.
[Full Text] [PDF]


Home page
Circ. Res.Home page
A. N. Clark, R. Youkey, X. Liu, L. Jia, R. Blatt, Y.-J. Day, G. W. Sullivan, J. Linden, and A. L. Tucker
A1 Adenosine Receptor Activation Promotes Angiogenesis and Release of VEGF From Monocytes
Circ. Res., November 26, 2007; 101(11): 1130 - 1138.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Reutershan, R. E. Cagnina, D. Chang, J. Linden, and K. Ley
Therapeutic Anti-Inflammatory Effects of Myeloid Cell Adenosine Receptor A2a Stimulation in Lipopolysaccharide-Induced Lung Injury
J. Immunol., July 15, 2007; 179(2): 1254 - 1263.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Loffler, J. C. Morote-Garcia, S. A. Eltzschig, I. R. Coe, and H. K. Eltzschig
Physiological Roles of Vascular Nucleoside Transporters
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1004 - 1013.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. Mohsenin, M. D. Burdick, J. G. Molina, M. P. Keane, and M. R. Blackburn
Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease
FASEB J, April 1, 2007; 21(4): 1026 - 1036.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Ryzhov, J. L. McCaleb, A. E. Goldstein, I. Biaggioni, and I. Feoktistov
Role of Adenosine Receptors in the Regulation of Angiogenic Factors and Neovascularization in Hypoxia
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 565 - 572.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
T. Kong, K. A. Westerman, M. Faigle, H. K. Eltzschig, and S. P. Colgan
HIF-dependent induction of adenosine A2B receptor in hypoxia
FASEB J, November 1, 2006; 20(13): 2242 - 2250.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
H. K. Eltzschig, P. Abdulla, E. Hoffman, K. E. Hamilton, D. Daniels, C. Schonfeld, M. Loffler, G. Reyes, M. Duszenko, J. Karhausen, et al.
HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
J. Exp. Med., December 5, 2005; 202(11): 1493 - 1505.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Linden
Adenosine in Tissue Protection and Tissue Regeneration
Mol. Pharmacol., May 1, 2005; 67(5): 1385 - 1387.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics